Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BCPC 
Balchem Corporation (BCPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: BCPC (1-star) is a SELL. SELL since 3 days. Profits (-5.31%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $196.67
1 Year Target Price $196.67
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.01% | Avg. Invested days 42 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.16B USD | Price to earnings Ratio 38.06 | 1Y Target Price 196.67 |
Price to earnings Ratio 38.06 | 1Y Target Price 196.67 | ||
Volume (30-day avg) 2 | Beta 0.92 | 52 Weeks Range 145.70 - 185.06 | Updated Date 06/30/2025 |
52 Weeks Range 145.70 - 185.06 | Updated Date 06/30/2025 | ||
Dividends yield (FY) 0.55% | Basic EPS (TTM) 4.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.16% | Operating Margin (TTM) 20.56% |
Management Effectiveness
Return on Assets (TTM) 7.54% | Return on Equity (TTM) 11.94% |
Valuation
Trailing PE 38.06 | Forward PE 33.22 | Enterprise Value 5323440786 | Price to Sales(TTM) 5.35 |
Enterprise Value 5323440786 | Price to Sales(TTM) 5.35 | ||
Enterprise Value to Revenue 5.52 | Enterprise Value to EBITDA 22.47 | Shares Outstanding 32617300 | Shares Floating 32445082 |
Shares Outstanding 32617300 | Shares Floating 32445082 | ||
Percent Insiders 0.36 | Percent Institutions 90.35 |
Analyst Ratings
Rating 2 | Target Price 196.67 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Balchem Corporation
Company Overview
History and Background
Balchem Corporation was founded in 1967. Initially focused on encapsulation technology, it evolved into a global leader in specialty performance ingredients and products for the food, nutrition, animal health, and medical sterilization industries.
Core Business Areas
- Human Nutrition & Health (HN&H): Provides ingredients and customized nutrient solutions to the food, beverage, and dietary supplement markets.
- Animal Nutrition & Health (ANH): Offers products and services for dairy, beef, poultry, swine, and companion animal markets. Includes chelated minerals and encapsulated nutrients.
- Specialty Products: Supplies ethylene oxide for medical device sterilization and provides performance-enhancing solutions for various industrial applications.
Leadership and Structure
Ted Harris is the Chairman, President, and CEO. The company has a functional organizational structure with dedicated teams for each business segment.
Top Products and Market Share
Key Offerings
- REBAUDIOSIDE M (Reb M): High-intensity sweetener used in food and beverage applications. Market share is growing, but specific figures are not publicly disclosed. Competitors include PureCircle (now part of Ingredion) and SweeGen.
- Chelated Minerals (Albion Minerals): Mineral amino acid chelates used in animal and human nutrition. Balchem is a major player in this market, but precise market share data is not readily available. Competitors include Zinpro Corporation and Novus International.
- Ethylene Oxide (EO): Used for sterilizing medical devices. Balchem is a key supplier. Market share data not readily available. Competitors include Dow and BASF.
Market Dynamics
Industry Overview
The specialty ingredients market is driven by increasing demand for healthier food options, growing awareness of animal health, and stringent sterilization requirements in healthcare.
Positioning
Balchem holds a strong position due to its proprietary encapsulation and chelation technologies, which provide a competitive advantage in terms of product performance and bioavailability.
Total Addressable Market (TAM)
The total addressable market for Balchem is estimated at billions of dollars across its various segments. Balchem is strategically positioned to capture a growing share of this market with its specialized product offerings. TAM is expected to grow due to trends in health/wellness and animal productivity.
Upturn SWOT Analysis
Strengths
- Proprietary Technologies (Encapsulation, Chelation)
- Strong Customer Relationships
- Diverse Product Portfolio
- Global Presence
- Experienced Management Team
Weaknesses
- Dependence on Raw Material Prices
- Exposure to Regulatory Changes
- Potential for Product Liability Claims
- High R&D Expenses
Opportunities
- Expanding into New Geographies
- Developing New Product Applications
- Acquiring Complementary Businesses
- Growing Demand for Health and Wellness Products
- Partnerships to expand offering for medical sterilization
Threats
- Competition from Larger Players
- Economic Downturns
- Changes in Consumer Preferences
- Raw Material Price Volatility
- Disruptive technologies
Competitors and Market Share
Key Competitors
- IFF
- DSM
- Ingredion
- Kerry
Competitive Landscape
Balchem differentiates itself through its specialty ingredients, proprietary technologies and strong customer relationships in niche markets. Other players focus on broader markets.
Major Acquisitions
Performance Chemicals & Ingredients (PC&I)
- Year: 2021
- Acquisition Price (USD millions): 65.5
- Strategic Rationale: Expanded Balchem's portfolio of specialty products and its presence in industrial markets.
Growth Trajectory and Initiatives
Historical Growth: Balchem has demonstrated consistent growth through organic expansion and strategic acquisitions.
Future Projections: Future growth is projected to be driven by increasing demand for its products in human and animal nutrition, as well as continued expansion in the specialty products segment.
Recent Initiatives: Recent initiatives include acquisitions to expand product offerings, investments in R&D, and efforts to enhance operational efficiency.
Summary
Balchem is a solid company with proprietary technology, focusing on specialty ingredients, showing consistent growth through strategic acquisitions. Its financial performance is strong, especially in Animal Nutrition and Health, but it faces risks from raw material prices and increased competition. Future opportunities lie in new applications and geographic expansion, enhancing their positioning.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Balchem Corporation Investor Relations
- Company Filings
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates may vary depending on the source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Balchem Corporation
Exchange NASDAQ | Headquaters Montvale, NJ, United States | ||
IPO Launch date 1986-06-03 | CEO, President & Chairman Mr. Theodore Lee Harris | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 1379 | Website https://www.balchem.com |
Full time employees 1379 | Website https://www.balchem.com | ||
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.